MoneyWorks4Me

The sales is pegged at Rs. 573.49 millions for the June 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 765.36 millions during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -137.27 millions as compared to Net Profit of Rs. 26.86 millions of corresponding quarter ended June 2024Operating profit Margin for the quarter ended June 2025 slipped to -45.02% as compared to 82.22% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 573.49 765.36 -25.07 573.49 765.36 -25.07 3182.30 3685.95 -13.66
Other Income 0.00 0.20 -100.00 0.00 0.20 -100.00 4.98 0.98 408.16
PBIDT -45.02 82.22 -154.76 -45.02 82.22 -154.76 363.00 174.92 107.52
Interest 40.44 37.63 7.47 40.44 37.63 7.47 149.33 139.17 7.30
PBDT -85.46 44.59 -291.66 -85.46 44.59 -291.66 213.67 35.75 497.68
Depreciation 43.81 38.73 13.12 43.81 38.73 13.12 163.78 146.32 11.93
PBT -129.27 5.86 -2305.97 -129.27 5.86 -2305.97 49.89 -110.57 -145.12
TAX 8.00 -21.00 -138.10 8.00 -21.00 -138.10 -19.35 -20.08 -3.64
Deferred Tax 8.00 -21.00 -138.10 8.00 -21.00 -138.10 -20.18 -22.00 -8.27
PAT -137.27 26.86 -611.06 -137.27 26.86 -611.06 69.24 -90.49 -176.52
Equity 158.28 158.28 0.00 158.28 158.28 0.00 158.28 158.28 0.00
PBIDTM(%) -7.85 10.74 -173.07 -7.85 10.74 -173.07 11.41 4.75 140.37

Mangalam Drugs&Org. Share Price

27.94 -0.01 (-0.04%)
18-Aug-2026 13:21 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1877.85
Dr. Reddys Labs. 1185.15
Cipla 1432.65
Lupin 2226.65
Zydus Lifesciences 1122.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: